Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects With Gout and Mild to Moderate Chronic Kidney Disease

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects With Gout and Mild to Moderate Chronic Kidney Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALLN 346 (Primary)
  • Indications Gout; Hyperuricaemia; Renal failure
  • Focus Adverse reactions; Proof of concept
  • Acronyms Study 202
  • Sponsors Allena Pharmaceuticals

Most Recent Events

  • 04 Jun 2024 Results of post hoc( (Study 202) and (Study 102) ) explaining Association between clinical and disease characteristics and detectable or undetectable baseline ctDNA in patients with metastatic uveal melanoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 21 Jun 2023 Status changed from recruiting to discontinued.
  • 19 Jul 2022 According to an Allena Pharmaceuticals media release, enrollment of the first two cohorts in gout patients with stage 2 (cohort A) and stage 3 (cohort B) chronic kidney disease (CKD) has been completed. topline safety and efficacy data from cohort A and cohort B are expected to be available later this quarter.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top